April

Brewster Drug, Inc.; Decision and Order (April 3, 2020)

Gregory L. Molden, M.D.; Decision and Order (April 3, 2020)

Wildlife Laboratories, Inc. (April 1, 2020)

Shertech Laboratories, LLC (April 1, 2020)

March

Final Rule: Placement of FUB-AMB in Schedule I (March 30, 2020)

Pisgah Laboratories, Inc. (March 24, 2020)

Sharp (Bethlehem), LLC (March 24, 2020)

Cargill, Inc. (March 24, 2020)

Johnson Matthey Inc. (March 24, 2020)

Controls To Enhance the Cultivation of Marihuana for Research in the United States (PDF) (March 23, 2020)

John O. Dimowo, M.D.; Decision and Order (PDF) (March 19, 2020)

Siegfried USA, LLC (March 19, 2020)

Navinta LLC (March 19, 2020)

Proposed Rule: Registration and Reregistration Fees for Controlled Substance and List I Chemical Registrants (PDF) (March 16, 2020)

Interim Final Rule: Placement of Cenobamate in Schedule V (March 10, 2020)

Caligor Pharma Services (March 10, 2020)

SpecGx LLC (March 10, 2020)

Sigma Aldrich Research (March 10, 2020)

Siemens Healthcare Diagnostics Inc. (March 10, 2020)

William S. Husel, D.O.; Decision and Order (March 10, 2020)

Johnson Matthey Inc. (March 10, 2020)

S&B Pharma, Inc.; Correction (March 10, 2020)

Arizona Department of Corrections (March 10, 2020)

February

Proposed Rule: Registration Requirements for Narcotic Treatment Programs with Mobile Components (February 26, 2020)

Scottsdale Research Institute (February 24, 2020)

Synthcon, LLC (February 24, 2020)

Stepan Company (February 24, 2020)

Irvine Labs, Inc. (February 24, 2020)

Patheon Pharmaceuticals, Inc. (February 24, 2020)

Chemtos, LLC (February 24, 2020)

Jaime C. David, M.D.; Decision and Order (February 24, 2020)

Research Triangle Institute (February 24, 2020)

PerkinElmer, Inc. (February 24, 2020)

60-Day Notice: Contractor Drug Use Statement (February 7, 2020)

Noramco Inc. (February 3, 2020)

Spocannabis LLC (February 3, 2020)

IsoSciences, LLC (February 3, 2020)

Shelton W. Barnes, M.D.; Decision and Order (February 3, 2020)

Theresa L. Wendt, N.P.; Decision and Order (February 3, 2020)

Andrzej Kazimierz Zielke, M.D.; Decision and Order (February 3, 2020)

Kambiz Haghighi, M.D.; Decision and Order (February 3, 2020)

Solomon Adu-Beniako, M.D.; Decision and Order (February 3, 2020)

Stepan Company (February 3, 2020)

January 2020

Interim Final Rule: Placement of Lasmiditan in Schedule V (January 31, 2020)

Proposed Rule: Placement of cyclopentyl fentanyl, isobutyryl fentanyl, para-chloroisobutyryl fentanyl, para-methoxybutyryl fentanyl, and valeryl fentanyl Into Schedule I (January 30, 2020)

Temporary Rule: Extension of Temporary Placement of cyclopentyl fentanyl, isobutyryl fentanyl, para-chloroisobutyryl fentanyl, para-methoxybutyryl fentanyl, and valeryl fentanyl in Schedule I (January 30, 2020)

Direct Final Rule: Additions to Listing of Exempt Chemical Mixtures (January 27, 2020)

Final Rule: Placement of 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA in Schedule I (January 24, 2020)

Final Rule: Removal of 6β-Naltrexol From Control (January 24, 2020)

Final Rule: Placement of Brexanolone in Schedule IV (January 24, 2020)

S&B Pharma, Inc. (January 17, 2020)

Report of Theft or Loss of Controlled Substance; DEA Form 106 (January 15, 2020)

Final Rule: Placement of Solriamfetol in Schedule IV (January 7, 2020)

December 2019

Johnson Matthey Pharmaceutical Materials Inc. (December 27, 2019)

Janssen Pharmaceuticals Inc. (December 27, 2019)

Lisa Hamilton, N.P.; Decision and Order (December 27, 2019)

Siegfried USA, LLC (December 27, 2019)

Myoderm (December 27, 2019)

Stanley Brothers Bio Tec Inc. (December 26, 2019)

Kinetochem LLC (December 26, 2019)

Royal Emerald Pharmaceuticals Research and Development (December 26, 2019)

Agronomed Pharmaceuticals (December 26, 2019)

Final Rule; Technical Correction (December 16, 2019)

Jeffrey D. Olsen, M.D.; Decision and Order (PDF) (December 16, 2019)

Meridian Medical Technologies (December 16, 2019)

Novitium Pharma LLC (December 16, 2019)

Mylan Pharmaceuticals Inc. (December 16, 2019)

DEA Supports the Use of Medication Assisted Treatment for Use Disorder: Message for DATA Waived Practitioners And Those Eligible To Become DATA Waived (PDF) (December 12, 2019)

Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020 (December 2, 2019)

November

Patheon API Manufacturing, Inc. (November 22, 2019)

S&B Pharma, Inc. (November 22, 2019)

Chattem Chemicals (November 22, 2019)

Janssen Pharmaceuticals, Inc. (November 22, 2019)

Epic Pharma, LLC (November 22, 2019)

Fresenius Kabi USA, LLC (November 22, 2019)

GE Healthcare (November 22, 2019)

Mylan Technologies Inc. (November 22, 2019)

Rhodes Technologies (November 12, 2019)

Cambrex Charles City (November 12, 2019)

Cambridge Isotope Lab (November 12, 2019)

Placement of Solriamfetol in Schedule IV (Correction) (November 8, 2019)

Importer of Controlled Substances Registration (November 5, 2019)

Organix, Inc. (November 5, 2019)

Noramco Inc. (November 5, 2019)

Halo Pharmaceuticals, Inc. (November 5, 2019)